English
Клинический случай: длительный ответ на осимертиниб при метастатическом немелкоклеточном раке легкого с редкой мутацией в 20 экзоне гена EGFR
DOI: https://dx.doi.org/10.18565/pharmateca.2024.7.112-116
Нелюбина Л.А., Реутова Е.В., Лактионов К.К., Строганова А.М.
1) Научно-исследовательский институт клинической онкологии им. академика РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина, Москва, Россия; 2) Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина, Москва, Россия
Литература
1. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–139. doi: 10.1056/NEJMoa040938. 2. Riely G.J., Politi K.A., Miller V.A., Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232–241. doi: 10.1158/1078-0432.CCR-06-0658. 3. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500. doi: 10.1126/science.1099314. 4. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–11. doi: 10.1073/pnas.0405220101. 5. Langer C.J. Epidermal growth factor receptor inhibition in mutationpositive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31:3303–6. doi: 10.1200/JCO.2013.49.8782. 6. Park K., Tan E.H., O’Byrne K. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–89. doi: 10.1016/S1470-2045(16)30033-X. 7. Soria J.C., Ohe Y., Vansteenkiste J. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125. doi: 10.1056/NEJMoa1713137. 8. Ramalingam S.S., Vansteenkiste J., Planchard D. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50. doi: 10.1056/NEJMoa1913662. 9. Russo A., Franchina T., Ricciardi G. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 2019;20:1431. doi: 10.3390/ijms20061431. 10. Gristina V., Malapelle U., Galvano A. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat Rev. 2020;85:101994. doi: 10.1016/j.ctrv.2020.101994. 11. Zhang T., Wan B., Zhao Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8:302–316. doi: 10.21037/tlcr.2019.04.12. 12. Ma W., Brodie S., Agersborg S. Significant improvement in detecting BRAF, KRAS, and EGFR mutations using next-generation sequencing as compared with FDA-cleared kits. Mol Diagn Ther. 2017;21:571–579. doi: 10.1007/s40291-017-0290-z. 13. Bauml J.M., Viteri S., Minchom A., et al. FP07.12 underdiagnosis of EGFR exon 20 insertion mutation variants: Estimates from NGS-based real-world datasets. J Thorac Oncol. 2021;16:S208– S209. 14. Arcila M.E., Nafa K., Chaft J.E., et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12:220–9. doi: 10.1158/1535-7163.MCT-12-0620. 15. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13:e23–31. doi: 10.1016/S1470-2045(11)70129-2. 16. Riess J.W., Gandara D.R., Frampton G.M., et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018;13:1560–68. doi: 10.1016/j.jtho.2018.06.019. 17. Vyse S., Huang P.H. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5. doi: 10.1038/s41392-019-0038-9. 18. Oxnard G.R., Lo P.C., Nishino M., et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179–84. doi: 10.1097/JTO.0b013e3182779d18. 19. Kumar A., Petri E.T., Halmos B., et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26:1742–1751. doi: 10.1200/JCO.2007.12.1178. 20. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–46. doi: 10.1093/jnci/dji055. 21. Robichaux J.P., Elamin Y.Y., Tan Z., al. Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20–Selective Kinase Inhibitor in Non–Small Cell Lung Cancer. Nat Med. 2018;24:638–46. doi: 10.1038/s41591-018-0007-9. 22. Park K., Haura E.B., Leighl N.B., et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021;39:3391–3402. doi: 10.1200/JCO.21.00662. 23. Zhou C., Ramalingam S.S., Kim T.M., et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021;7:e214761. doi: 10.1001/jamaoncol.2021.4761. 24. Kobayashi Y., Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179–1186 25. Kohsaka S., Nagano M., Ueno T. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med. 2017;9:eaan6566. doi: 10.1126/scitranslmed.aan6566. 26. Lin Y.T., Liu Y.N., Wu S.G. Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18:324–332.e1. doi: 10.1016/j.cllc.2016.12.014. 27. Naidoo J., Sima C.S., Rodriguez K. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;121:3212–3220. doi: 10.1002/cncr.29493. 28. Wu J.Y., Yu C.J., Shih, J.Y. Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20:e620–e630. doi: 10.1016/j.cllc.2019.06.018. 29. Ma C., Zhang J., Tang D. Tyrosine kinase inhibitors could be effective against non-small cell lung cancer brain metastases harboring uncommon EGFR mutations. Front Oncol. 2020;10:224. doi: 10.3389/fonc.2020.00224. 30. Schuler M., Wu Y.L., Hirsh V.First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380–90. doi: 10.1016/j.jtho.2015.11.014. 31. Hoffknecht P., Tufman A., Wehler T. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10:156–163. doi: 10.1097/JTO.0000000000000380. 30. Park S., Lee M.H., Seong M. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol. 2020;31:1397–1404. doi: 10.1016/j.annonc.2020.06.017. 33. Reungwetwattana T., Nakagawa K., Cho B.C. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290–3297. 34. Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 2018;14:1117–1132. doi: 10.2217/fon-2017-0636. 35. Клинические рекомендации Министерства Здравоохранения Российской Федерации «Злокачественные новообразования бронхов и легкого», 2022 г. 36. Passaro A., Mok T., Peters S., et al. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol. 2021;16(5):764–773. doi: 10.1016/j.jtho.2020.12.002.
Об авторах / Для корреспонденции
Автор для связи: Лидия Александровна Нелюбина, к.м.н., науч. сотр. отделения противоопухолевой лекарственной терапии №3, Научно-исследовательский институт клинической онкологии им. академика РАН и РАМН Н.Н. Трапезникова, Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина, Москва, Россия; nelyubina.la@gmail.com ORCID:
Л.А. Нелюбина (L.A. Nelyubina), https://orcid.org/0009-0006-0796-6993
Е.В. Реутова (E.V. Reutova), https://orcid.org/0000-0002-2154-3376
К.К. Лактионов (K.K. Laktionov), https://orcid.org/0000-0003-4469-502X
А.М. Строганова (A.M. Stroganova), https://orcid.org/0000-0002-7297-5240
Похожие статьи
При полном или частичном использовании материалов ссылка на журнал «ФАРМАТЕКА» обязательна.
